Cullen/Frost Bankers, Inc. Allogene Therapeutics, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $8.43 Billion
- Q3 2025
A detailed history of Cullen/Frost Bankers, Inc. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 4,953 shares of ALLO stock, worth $6,092. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,953
Previous 4,951
0.04%
Holding current value
$6,092
Previous $5,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ALLO
# of Institutions
182Shares Held
138MCall Options Held
76.6KPut Options Held
36.2K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$23 Million1.5% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$20.2 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il14MShares$17.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.02MShares$11.1 Million0.0% of portfolio
-
Primecap Management CO Pasadena, CA7.08MShares$8.71 Million0.01% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $177M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...